Gene transfer as a tool to induce therapeutic vascular growth (Q35141791)

6 August 2017

1 reference

title

Gene transfer as a tool to induce therapeutic vascular growth (English)

1 reference

6 August 2017

1

1 reference

6 August 2017

Kari Alitalo

2

0 references

language of work or name

English

0 references

publication date

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

694-701

1 reference

Cardiovascular gene therapy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene therapy with viral vectors

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Virus treatment questioned after gene therapy death

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Lentiviral vectors: turning a deadly foe into a therapeutic agent

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

AAV vectors: is clinical success on the horizon?

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Expression of vascular endothelial growth factor from a defective herpes simplex virus type 1 amplicon vector induces angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

VEGF gene delivery to muscle: potential role for vasculogenesis in adults

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Regulated gene expression systems

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene silencing in mammals by small interfering RNAs

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene therapy. Second child in French trial is found to have leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

The delivery of angiogenic factors to the heart by microsphere therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Specialization of tumour vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Clinical applications of angiogenic growth factors and their inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

A model for gene therapy of human hereditary lymphedema

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Therapeutic lymphangiogenesis with human recombinant VEGF-C.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Insights into the molecular pathogenesis and targeted treatment of lymphedema

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Lymphangiogenic gene therapy with minimal blood vascular side effects

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Assessment of risks associated with cardiovascular gene therapy in human subjects

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

The role of fibroblast growth factors in vascular development

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Fibroblast growth factors and their receptors

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Fibroblast growth factor receptors (FGFRs) and their roles in limb development

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Monocyte Chemotactic Protein-1 Increases Collateral and Peripheral Conductance After Femoral Artery Occlusion

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Del1 induces integrin signaling and angiogenesis by ligation of alphaVbeta3.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Stimulation of angiogenesis by Cyr61 gene: a new therapeutic candidate

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

FrzA, a secreted frizzled related protein, induced angiogenic response

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Tissue repair with a therapeutic transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Induction of angiogenesis in a mouse model using engineered transcription factors

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Recombinant AAV vector encoding human VEGF165 enhances wound healing.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

https://api.crossref.org/works/10.1038%2FNM0603-694

1 reference

7 January 2021

Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene transfer in regenerating muscle

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Reversal of experimental diabetic neuropathy by VEGF gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Defining gene transfer before expecting gene therapy: putting the horse before the cart

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Periadventitial lacZ gene transfer to pig carotid arteries using a biodegradable collagen collar or a wrap of collagen sheet with adenoviruses and plasmid-liposome complexes

1 reference

https://api.crossref.org/works/10.1038%2FNM0603-694

7 January 2021

Identifiers

DOI

10.1038/NM0603-694

1 reference

6 August 2017

1 reference